Schweiz - Italienisch - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - nifedipinum - retardtabletten - nifedipinum 20 mg, excipiens pro compresso haze. - calciumantagonist - synthetika

Schweiz - Italienisch - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - nifedipinum, atenololum - capsule - nifedipinum 20 mg, atenololum 50 mg, excipiens pro capsula. - hypertonie - synthetika

Schweiz - Italienisch - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - nifedipinum, atenololum - capsule - nifedipinum 20 mg, atenololum 50 mg. pulver: excipiens per la capsula. - hypertonie, angina pectoris - sintetica umana

Italien - Italienisch - Ministero della Salute

chemifarma s.p.a. - colistina solfato - colistina solfato - 120 g - colistin

Italien - Italienisch - Ministero della Salute

helm ag - tribenuron; - granulare idrodispersibile - 75.0 g i valori indicati sono per 100 g di prodotto. - diserbante

Italien - Italienisch - Ministero della Salute

vetoquinol sa - acido tolfenamico - acido tolfenamico - 4 g - tolfenamic acid

Schweiz - Italienisch - Swissmedic (Swiss Agency for Therapeutic Products)

haleon schweiz ag - terbinafinum - filmogeni soluzione - terbinafinum 10 mg ut terbinafini hydrochloridum, acrylates et octylacrylamidi polymerisatum, triglycerida media, hydroxypropylcellulosum, ethanolum 96 per centum 863.75 mg, ad solutionem pro 1 g. - provocare - synthetika

Europäische Union - Italienisch - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - prodotti immunologici per felidae, - gatti - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. insorti di immunità sono stati dimostrati 1 settimana dopo il corso di vaccinazione primaria per componenti di rinotracheite, calicivirus e chlamydophila felis. la durata dell'immunità è di 1 anno dopo l'ultima (ri)vaccinazione.

Europäische Union - Italienisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - prodotti immunologici per felidae, - gatti - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. insorti di immunità sono stati dimostrati una settimana dopo il corso di vaccinazione primaria per rinotracheite, calicivirus, chlamydophila felis e componenti di panleucopenia. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Italienisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - prodotti immunologici per felidae, - gatti - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.